© Christian Sticherling, David Conen 2017
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the  general population. Due to the demographic change with  increasing life expectancy, the occurrence of AF is expected to  further increase in the near future. Patients suffering from AF are  at risk for serious complications, such as a 4-5 fold higher risk of  stroke, and a more than 10-fold higher risk of heart failure  compared to individuals without AF. In addition, recent studies  found a reduced quality of life and increased risk of cognitive  impairments and dementia among AF patients.   Hence, AF has become a major public health problem in  Switzerland. Improving treatment strategies that minimize the risk  of disabling events such as stroke, heart failure or dementia in this  growing patient population will therefore have a substantial  positive impact on public health. Further, improving medical care  and clinical outcomes holds a great potential of being cost-  effective or even cost-saving, as these factors are significantly  associated with costs of care.  

Introduction

Swiss-AF is funded by the Swiss National Science Foundation (SNSF).
Home News Flyer Study Overview Organisation Collaboration Contact Links Study Overview